



Michael Scharl

Kontakt

Michael Scharl

Publikationen (14)

Yoganathan P, Rossel J, Jordi S, Franc Y, Biedermann L, Misselwitz B, Hausmann M, Rogler G, Scharl M, Frey-Wagner I, Swiss IBD Cohort Study Group. Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients. *BMC Gastroenterol* 2021; 21:310.

Schreiner P, Misselwitz B, von Känel R, Rogler G, Juillerat P, Pittet V, Vavricka S, Scharl M, Greuter T, Baumann C, Valko P, Biedermann L, Rossel J, Swiss IBD Cohort Study Group. Fatigue in inflammatory bowel disease and its impact on daily activities. *Aliment Pharmacol Ther* 2020; 53:138-149.

Tcymbarevich I, Misselwitz B, de Vallière C, Rogler G, Ruiz P, Seuwen K, Scharl M, Wagner C, Kullak-Ublick G, Lang S, Cosin-Roger J, Spalinger M, Obialo N, Rossel J, Eloranta J, Swiss IBD Cohort Study Group. The impact of the rs8005161 polymorphism on G protein-coupled receptor GPR65 (TDAG8) pH-associated activation in intestinal inflammation. *BMC Gastroenterol* 2019; 19:2.

Vavricka S, Biedermann L, Michetti P, Straumann A, Misselwitz B, Scharl M, Manser C, Greuter T, Zeitz J, Frei P, Borovicka J, Seibold F, Schoepfer A, Rogler G, Spasojevic M. Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey. *Dig Dis* 2017; 35:423-432.

Vavricka S, Misselwitz B, Scharl M, Heinrich H, Manser C, Safroneeva E, Raja Ali R, Rogler G, Schoepfer A, Greuter T, Zeitz J, Biedermann L, Juillerat P, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. *Inflamm Bowel Dis* 2017

Zeitz J, Rogler G, Fried M, Sulz M, Vavricka S, Scharl S, Misselwitz B, Frei P, Biedermann L, Labenz C, Fournier N, Scharl M. Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort. *Inflamm Intest Dis* 2017; 1:172-181.

Bontà J, Rogler G, Fried M, Scharl S, Vavricka S, Sulz M, Biedermann L, Frei P, Zeitz J, Scharl M. Cytomegalovirus disease in inflammatory bowel disease: epidemiology and disease characteristics in a large single-centre experience. *Eur J Gastroenterol Hepatol* 2016; 28:1329-34.

Spalinger M, Scharl M, Rogler G, Fried M, Vavricka S, Scharl S, Frei P, Sulz M, Rossel J, Biedermann L, Zeitz J. Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort. *PloS one* 2016; 11:e0160215.

Madanchi M, Rogler G, Vavricka S, Frei P, Biedermann L, Sulz M, Scharl S, Samaras P, Barthel C, Zeitz J, Scharl M. Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience. *Digestion* 2016; 94:1-8.

Vögelin M, Rogler G, Fried M, Sulz M, Zeitz J, Scharl S, Vavricka S, Frei P, Biedermann L, Scharl M. The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. *PloS one* 2016; 11:e0155218.

Spalinger M, Scharl M, Rogler G, Fried M, Vavricka S, Scharl S, Frei P, Sulz M, Rossel J, Zeitz J, Biedermann L, Voegelin M. The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort. *Digestion* 2016; 93:182-92.

Barthel C, Rogler G, Wiegand N, Sulz M, Fried M, Vavricka S, Frei P, Scharl M, Scharl S, Wiegand S, Biedermann L. Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?--a patient survey. Nutr J 2015; 14:78.

Scharl M, Bode B, Rushing E, Knuth A, Rordorf T. Uncommon case of brain metastasis in a patient with a history of heavy smoking. Curr Oncol 2014; 21:e728-31.

Vavricka S, Michetti P, Straumann A, Seibold F, Scharl M, Sauter B, de Saussure P, Rogler G, Manz M, Geyer M, Felley C, Binek J, Banský G, Schoepfer A, for the Swiss IBDnet. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflamm Bowel Dis 2010

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch